Publication Name	World Journal of Gastroenterology
Manuscript ID	6558
Country	Japan

Received	2013-10-24 13:51
Peer-Review Started	2013-10-25 09:41
To Make the First Decision	2013-12-26 11:20
Return for Revision	2013-12-26 19:51
Revised	2014-01-09 15:21
Second Decision	2014-04-09 08:07
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-04-09 08:52
Articles in Press	2014-05-23 10:14
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-08-18 21:05
Publish the Manuscript Online	2014-09-07 13:31

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	What make differences in the outcome of adjuvant treatments for resected gastric cancer?
Manuscript Source	Invited Manuscript
All Author List	Toshifusa Nakajima and Masashi Fujii
Funding Agency and Grant Number
Corresponding Author	Toshifusa Nakajima, MD, PhD, Department of Gastrointestinal Surgery, Cancer Institute Ariake Hospital, Japanese Foundation for Cancer Research. 3-10-6, Ariake, Koto-ku, Tokyo 135-8550, Japan. nakajima@jfcr.or.jp
Key Words	Resected gastric cancer; Phase Ⅲ clinical trial; Adjuvant and neo-adjuvant therapy; Chemoradiotherapy; Review
Core Tip	Recent positive results of adjuvant clinical trials for gastric cancer are attributed to new approaches different from previous negative trials. Inclusion of novel effective drug (S-1: ACTS-GC) and new combination of drugs (capecitabine and oxaliplatin: CLASSIC/Cisplatin and 5-fluorouracil: FNCLCC/FFCD), combination of chemotherapy and radiotherapy (SWOG INT0116), and combination of different timing (pre- and postoperative: MAGICC), might have contributed to yield positive results after curative D2 surgery. D2 surgery is going to be adopted as recommended treatment in Eastern and Western countries, and should be the baseline treatment to minimize the amount of residual tumor in future trials of adjuvant treatment.
Publish Date	2014-09-07 13:31
Citation	Nakajima T, Fujii M. What make differences in the outcome of adjuvant treatments for resected gastric cancer? World J Gastroenterol 2014; 20(33): 11567-11573
URL	http://www.wjgnet.com/1007-9327/full/v20/i33/11567.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i33.11567

Full Article (PDF)	WJG-20-11567.pdf
Full Article (Word)	WJG-20-11567.doc
Manuscript File	6558-review.doc
Answering Reviewers	6558-Answering reviewers.pdf
Copyright License Agreement	6558-Copyright assignment.pdf
Peer-review Report	6558-Peer review(s).pdf
Scientific Editor Work List	6558-Scientific editor work list.doc